Post Marketing Surveillance Study on Emselex After Launch in Germany

• Status: Completed
• Trial end date: 2006-02-01
• Target enrollment: 0
• Participant gender: All

Summary

• Data are obtained of Emselex in routine treatment of Overactive Bladder. The general objectives are to evaluate the product safety, compatibility, efficacy and patient acceptance.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Darifenacin

Criteria

Inclusion Criteria:

• Patients who are treated with Emselex for Overactive Bladder

Exclusion Criteria:

• Exclusion criteria are the contraindications as specified in the German product information